scholarly journals Therapeutic Drug Monitoring of Carbamazepine: A 20-Year Observational Study

2021 ◽  
Vol 10 (22) ◽  
pp. 5396
Author(s):  
Grzegorz Grześk ◽  
Wioleta Stolarek ◽  
Michał Kasprzak ◽  
Elżbieta Grześk ◽  
Daniel Rogowicz ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Therapeutic Range ◽  
Drug Monitoring ◽  
First Generation ◽  
Suicide Attempts ◽  
Anticonvulsant Drug ◽  
Therapeutic Drug ◽  
Therapeutic Level ◽  
Suspected Drug

Background: Carbamazepine (CBZ) is a first-generation anticonvulsant drug. Hence, in certain cases, therapeutic drug monitoring (TDM) supports pharmacotherapy. Methods: The presented research was based on a retrospective analysis including 710 ambulatory and hospitalized patients treated with CBZ between the years 1991 and 2011. The method used for the determination of the CBZ concentration was fluorescence polarization immunoassay (FPIA) performed using an Abbott GmbH TDx automatic analyzer, with the therapeutic range for carbamazepine being 4–12 µg/mL. Results: The therapeutic range was observed more often in patients between 3 and 17 years of age compared with the population ≥18 years of age (73.5% vs. 68.8%). The therapeutic level was exceeded less frequently in the population between 3 and 17 years of age despite them being given a significantly higher dose per kilogram of body weight than in the population ≥18 years of age (13.64 mg/kg vs. 10.43 mg/kg, p < 0.0001). Patients ≥18 years of age were statistically significantly more likely to be in the group with a suspected drug overdose (73.9% vs. 26.1%), and suicide attempts only occurred in elderly patients (100.0% vs. 0.0%, p = 0.003). Conclusion: The results of the TDM of CBZ showed that only 71% of all samples were at the therapeutic level. To ensure the maximum efficacy and safety of the therapy, it is necessary to monitor the concentration of CBZ regardless of sex and age.

scholarly journals Benefits of Therapeutic Drug Monitoring of First Line Antituberculosis Drugs

2020 ◽  
Vol 20 (2) ◽  
pp. 45-55
Author(s):  
K Prso ◽  
N Zidekova ◽  
M Dohal ◽  
I Porvaznik ◽  
M Prso ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Plasma Drug Concentration ◽  
Therapeutic Drug ◽  
Plasma Drug ◽  
Therapeutic Level ◽  
First Line ◽  
Antituberculosis Drugs ◽  
Health Related

AbstractTuberculosis is an airborne infectious disease that remains a huge global health-related issue nowadays. Despite constant approvals of newly developed drugs, the use of first-line antituberculosis medicines seems reasonable in drug-susceptible Mycobacterium tuberculosis strains. Therapeutic drug monitoring presents a useful technique for the determination of plasma drug concentration to adjust appropriate dose regimes. In tuberculosis treatment, therapeutic drug monitoring is aiding clinicians in selecting an optimal therapeutic level, which is essential for the personalisation of therapy. This review is aimed at clarifying the use of therapeutic drug monitoring of the first-line antituberculosis drugs in routine clinical practice.

scholarly journals Therapeutic Drug Monitoring of Second- and Third-Generation Antiepileptic Drugs: Insights From a College of American Pathologists Proficiency Testing Survey

2021 ◽  
Author(s):  
Matthew D. Krasowski ◽  
Thomas A. Long ◽  
Christine L. H. Snozek ◽  
Annabel Dizon ◽  
Barbarajean Magnani ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Antiepileptic Drugs ◽  
Proficiency Testing ◽  
Drug Monitoring ◽  
First Generation ◽  
Therapeutic Drug ◽  
Third Generation ◽  
Enzyme Immunoassays ◽  
Steady Growth ◽  
Survey Results

Context.— Therapeutic drug monitoring has traditionally been widely used for first-generation antiepileptic drugs (AEDs) such as carbamazepine and phenytoin. The last 2 decades have seen the introduction of second- and third-generation AEDs (eg, lamotrigine, levetiracetam, and topiramate) into clinical practice. Objective.— To use data from the College of American Pathologists Therapeutic Drug Monitoring, Extended proficiency testing survey to determine the performance of assays used for therapeutic drug monitoring of newer AEDs, including comparison of enzyme immunoassay and chromatographic techniques. Design.— Six years of proficiency testing surveys were reviewed (2013–2018). Results.— Steady growth was seen in participant volumes for newer AEDs. The analytical performance of automated enzyme immunoassays for lamotrigine, levetiracetam, and topiramate was similar to that of chromatographic methods, consistent with published literature using patient samples for comparisons. The majority of participating laboratories now use enzyme immunoassays to measure levetiracetam. Conclusions.— Survey results reflect steadily growing interest in therapeutic drug monitoring of newer AEDs. The increasing availability of robust immunoassays for new AEDs should facilitate their clinical utility, especially for clinical laboratories that do not perform chromatographic assays for therapeutic drug monitoring.

Determination of Olanzapine for Therapeutic Drug Monitoring in Schizophrenia Patients by LC/MS Method

2018 ◽  
pp. e4468 ◽  
Author(s):  
Mevlut Albayrak ◽  
Yucel Kadioglu ◽  
Mehmet Emrah Yaman ◽  
Onur Senol ◽  
Elif Oral
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Therapeutic Drug
Sign in / Sign up

Export Citation Format

Share Document